🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase II

Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
2,640

Quick answer

Oncology Phase II programs: NovaPharmaNews indexes 2,640 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 17 of 55

  1. DS-3939a

    Daiichi Sankyo

    Metastatic Solid Tumor, Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  2. DS-8201a

    Ningbo Cancer Hospital

    Metastatic Breast Cancer HR+, HER2-

    phase 2 small molecule active

    1 trial

  3. DS-8201a

    Daiichi Sankyo

    Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (IHC) 0 Breast Cancer

    phase 2 small molecule active

    1 trial

  4. DS-8201a

    AstraZeneca AB

    HER2 Expressing Tumors

    phase 2 small molecule active

    1 trial

  5. DS-8201a

    AstraZeneca AB

    Treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless of tumor histology

    phase 2 small molecule active

    1 trial

  6. DURVALUMAB

    Fondazione Telethon ETS

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  7. DURVALUMAB , Ifinatamab Deruxtecan, MK-6070

    Merck Sharp and Dohme

    Small cell lung cancer

    phase 2 small molecule active

    1 trial

  8. DURVALUMAB, PACLITAXEL ALBUMIN-BOUND, Ceralasertib

    Fondazione Telethon ETS

    ADVANCED TRIPLE NEGATIVE BREAST CANCER

    phase 2 small molecule active

    1 trial

  9. DYP688

    Novartis Pharmaceuticals

    Metastatic uveal melanoma, other GNAQ/11 mutant melanomas (e.g. skin or mucosal melanoma)

    phase 2 small molecule active

    1 trial

  10. DZR123, DZR123, ENZALUTAMIDE

    Novartis Pharmaceuticals

    advanced, solid, relapsed tumors / advanced tumors: human lymphomas / solid human tumor indications (urothelial carcinoma, or other advanced/metastatic solid tumors, ovarian clear cell cancer, endometrial carcinoma, lymphoma including peripheral T-cell Lymphoma and GCBDLBCL, malignant pleural or peritoneal mesothelioma, metastatic castration - resistant prostate cancer (mCRPC))

    phase 2 small molecule active

    1 trial

  11. Dabogratinib (TYRA-300) 60mg

    Tyra Biosciences

    Low Grade Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  12. Dabrafenib

    Novartis Pharmaceuticals

    Cancer

    phase 2 small molecule completed

    1 trial

  13. Dacogen 50 mg powder for concentrate for solution for infusion., Venclyxto 50 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Venclyxto 10 mg film-coated tablets

    Fondazione Telethon ETS

    Acute Myeloid Leukemia secondary to myeloproliferative neoplasms

    phase 2 small molecule active

    1 trial

  14. Dalpiciclib

    The First People's Hospital of Lianyungang

    Early Breast Cancer

    phase 2 small molecule active

    1 trial

  15. Danggui Buxue Tang

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  16. Daraxonrasib

    Revolution Medicines

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  17. Darinaparsin

    Alaunos Therapeutics

    Hematologic Neoplasms

    phase 2 small molecule completed

    1 trial

  18. Darinaparsin

    Alaunos Therapeutics

    HEPATOCELLULAR CARCINOMA

    phase 2 small molecule active

    1 trial

  19. Darleukin, Fibromun

    Philogen S.p.A.

    Patients with high-risk, locally advanced (non-metastatic, node negative, single or multifocal), Basal Cell Carcinoma (BCC) or cutaneous Squamous Cell Carcinoma (cSCC) amenable to intratumoral injection, not eligible to surgery or radiation therapy according to the evaluation of a local interdisciplinary tumor board or who refuse surgery or radiation therapy and for whom a histological evaluation is available according to international guidelines.

    phase 2 small molecule active

    1 trial

  20. Darleukin, Fibromun

    Philogen S.p.A.

    locally advanced basal cell carcinoma patients

    phase 2 small molecule active

    1 trial

  21. Darolutamide+ADT

    The First People's Hospital of Lianyungang

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  22. Darovasertib

    Hospital Authority, Hong Kong

    Ocular Melanoma

    phase 2 small molecule completed

    1 trial

  23. Dasatinib

    Bristol-Myers Squibb

    Chronic Myeloid Leukemia

    phase 2 small molecule completed

    1 trial

  24. Dasatinib

    Takeda

    Acute Lymphoblastic Leukemia

    phase 2 small molecule terminated

    1 trial

  25. Datopotamab deruxtecan

    Daiichi Sankyo

    Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  26. Datopotamab deruxtecan

    AstraZeneca AB

    Locally Advanced Inoperable or Metastatic Breast Cancer Refractory to Endocrine Therapy

    phase 2 small molecule active

    1 trial

  27. Dazostinag

    Takeda

    Solid Neoplasms

    phase 2 small molecule completed

    1 trial

  28. Debio 4228, Debio 4228

    Alphapharm Pty Ltd

    advanced prostate cancer

    phase 2 small molecule active

    1 trial

  29. Decitabine

    Shanghai Tong Ren Hospital

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  30. Decitabine

    The University of Hong Kong

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  31. Decitabine

    Teva Pharma GmbH

    Acute Myeloid Leukemia

    phase 2 small molecule completed

    1 trial

  32. Decitabine

    CATALYST PHARMACEUTICALS, INC.

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  33. Decitabine

    Karyopharm Therapeutics Inc

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  34. Decoy20

    BRIGHT MINDS BIOSCIENCES INC.

    Solid Tumor, Adult

    phase 2 small molecule active

    1 trial

  35. Defosbarasertib, IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    First-line patients with extensive disease small-cell lung cancer (SCLC)

    phase 2 small molecule active

    1 trial

  36. Degarelix

    Regeneron UK Limited

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  37. Demcizumab

    Mereo BioPharma Group plc

    Pancreatic Cancer

    phase 2 small molecule completed

    2 trials

  38. Dendritic Cell Vaccination

    Quantum Biopharma

    Breast Cancer

    phase 2 mab active

    1 trial

  39. Dendritic Cell/Tumor Fusion Vaccine

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 mab terminated

    1 trial

  40. Denosumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Cancer

    phase 2 small molecule active

    1 trial

  41. Dental stent

    Hospital Authority, Hong Kong

    Nasopharyngeal Carcinoma

    phase 2 other active

    1 trial

  42. Derazantinib

    Basilea Pharmaceutica

    Gastric Adenocarcinoma

    phase 2 small molecule terminated

    1 trial

  43. Description and Composition of the Placebo • Placebo oil solution matching the Cannabis Extract Avextra 10/10 Solution. • Pharmaceutical form: solution (oil) • Route of administration: oral • Storage: Store tightly closed below 25°C and protected from light like the verum form. • Country of origin: Italy., Cannabis Extract Avextra 10/10 Solution

    Fondazione Telethon ETS

    Patients with advanced oncologic disease receiving active treatment with WHO level II or III opioids and adjuvants therapies

    phase 2 small molecule active

    1 trial

  44. Dexamethason 4 mg JENAPHARM®, Dexamethasone Tablets BP 2.0mg, CRISANTASPASE, Dexamethason 0,5 mg JENAPHARM®, Vincristine Sulfate 1 mg/ml solution for injection, Oncaspar 750 U/ml powder for solution for injection/infusion., Dexamethasone 3.3 mg/mL Solution for injection, MITOXANTRONE HYDROCHLORIDE, BESPONSA 1 mg powder for concentrate for solution for infusion

    Pfizer Australia Pty Ltd

    Acute Lymphoblastic Leukemia (ALL)

    phase 2 small molecule active

    1 trial

  45. Dexamethason 4 mg JENAPHARM®, evorpacept, Isatuximab, Dexamethason 8 mg JENAPHARM®, Isatuximab

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  46. Dexamethason 8 mg JENAPHARM®, SAR445761 - belumosudil, Isatuximab, Isatuximab, Dexamethason 4 mg JENAPHARM®

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  47. Dexamethasone

    The First People's Hospital of Lianyungang

    Precursor B-Cell Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  48. Dexamethasone

    Kura Oncology

    Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology Phase II programs exist?

2,640 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.